Haemonetics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
02/06/2025 | HAE | Haemonetics | FY | 2025 | $4.50 | $4.70 | $4.59 | $1.35B | $1.37B | $1.39B | Get Alert |
11/07/2024 | HAE | Haemonetics | FY | 2025 | $4.45 | $4.75 | $4.59 | $1.38B | $1.41B | $1.40B | Get Alert |
08/08/2024 | HAE | Haemonetics | FY | 2025 | $4.45 | $4.75 | $4.60 | $1.38B | $1.41B | $1.40B | Get Alert |
05/09/2024 | HAE | Haemonetics | FY | 2025 | $4.45 | $4.75 | $4.40 | $1.38B | $1.41B | $1.37B | Get Alert |
02/08/2024 | HAE | Haemonetics | FY | 2024 | $3.90 | $4.00 | $3.89 | $1.29B | $1.31B | $1.27B | Get Alert |
12/12/2023 | HAE | Haemonetics | FY | 2024 | $3.75 | $3.95 | $3.89 | $1.26B | $1.29B | $1.27B | Get Alert |
11/02/2023 | HAE | Haemonetics | FY | 2024 | $3.75 | $3.95 | $3.81 | $1.25B | $1.27B | $1.26B | Get Alert |
08/08/2023 | HAE | Haemonetics | FY | 2024 | $3.60 | $3.90 | $3.59 | $1.24B | $1.27B | $1.24B | Get Alert |
05/11/2023 | HAE | Haemonetics | FY | 2024 | $3.45 | $3.75 | $3.40 | $1.22B | $1.25B | $1.22B | Get Alert |
02/07/2023 | HAE | Haemonetics | FY | 2023 | $2.90 | $3.00 | $2.92 | $1.14B | $1.16B | $1.14B | Get Alert |
11/07/2022 | HAE | Haemonetics | FY | 2023 | $2.70 | $3.00 | $2.79 | $1.11B | $1.14B | $1.09B | Get Alert |
08/10/2022 | HAE | Haemonetics | FY | 2023 | $2.60 | $2.90 | $2.73 | $1.07B | $1.10B | $1.06B | Get Alert |
05/10/2022 | HAE | Haemonetics | FY | 2023 | $2.50 | $2.90 | $2.75 | $1.04B | $1.08B | $1.03B | Get Alert |
02/08/2022 | HAE | Haemonetics | FY | 2022 | $2.45 | $2.55 | $2.53 | $974.92M | $992.33M | $996.92M | Get Alert |
11/09/2021 | HAE | Haemonetics | FY | 2022 | $2.40 | $2.65 | $2.76 | $983.62M | $1.02B | $1.01B | Get Alert |
08/11/2021 | HAE | Haemonetics | FY | 2022 | $2.60 | $3.00 | $2.78 | $983.62M | $1.03B | $1.00B | Get Alert |
05/13/2021 | HAE | Haemonetics | FY | 2022 | $2.60 | $3.00 | $3.48 | $983.62M | $1.03B | $1.02B | Get Alert |
The most recent guidance for Haemonetics (HAE) was reported on February 6, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $4.50 to $4.70, compared to the estimated EPS of $4.59. Additionally, Haemonetics forecasted revenue between $1.35B and $1.37B for the quarter.
Browse guidance and forecast on all stocks.